FDA lehnte VP-102 zur Zulassung ab
endpts.com/...-month-after-flagging-application-deficiencies/
Zahlen für Q1/20
- keine Umsätze
- Verlust 10 Mio. $
- Cash 88 Mio. $
- MK 163 Mio. $
" ..the Company believes will be sufficient to support planned operations, including expenses for the potential commercialization of the Company’s lead product candidate, VP-102, as well as the ongoing development of the compound for additional indications, including common warts and external genital warts, and the development of VP-103 for plantar warts, at least through the second quarter of 2021."
investors.verrica.com/news-releases/...quarter-2020-financial